

**Summary of Consolidated Financial Results for the First Three Months of
the Year Ending March 31, 2022 (FY2021)
<Based on Japanese GAAP>**

August 2, 2021

Company name: ASKA Pharmaceutical Holdings Co., Ltd
 Stock exchange listing: Tokyo
 Stock code: 4886 URL <https://www.aska-pharma-hd.co.jp/english/>
 Representative : President and Representative Director Takashi Yamaguchi
 Inquiries : General Manager Corporate Planning Department Hideaki Kobayashi TEL +81-3-5484-8366
 Scheduled date to file Securities Report : August 10, 2021
 Scheduled date to commence dividend payments : -
 Preparation of supplementary material on financial results : Yes
 Holding of financial results meeting : No

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the three months ended June 30, 2021 (from April 1, 2021 to June 30, 2021)

(1) Consolidated operating results

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
First three months of FY2021	14,221	-	1,188	-	1,329	-	1,098	-
First three months of FY2020	-	-	-	-	-	-	-	-

Note: Comprehensive income First three months of FY2021 (Millions of yen) 986 (-%)
 First three months of FY2020 (Millions of yen) - (-%)

	Earnings per share	Diluted earnings per share
	Yen	Yen
First three months of FY2021	38.72	-
First three months of FY2020	-	-

Note: There are no financial results for the previous first quarter because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of June 30, 2021	81,717	45,313	55.5
As of March 31, 2021	-	-	-

Reference: Tangible net worth First three months of FY2021 (Millions of yen) 45,313
 First three months of FY2020 (Millions of yen) -

Note: There are no financial results for the previous quarter because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2021	-	-	-	-	-
Year ending March 31, 2022	-	-	-	-	-
Year ending March 31, 2022 (Forecast)	-	7.00	-	7.00	14.00

Note 1. Revision from dividend forecast currently announced: No

Note 2. There are no financial results for the previous quarter because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

3. Forecast of consolidated financial results for the year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	52,000	-	1,500	-	1,500	-	800	-	29.33

Note 1. Revision from dividend forecast currently announced: No

Note 2. There are no percentage changes from the previous quarter because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

※ Notes

- (1) Changes in significant subsidiaries during the first three months of FY2021
(changes in specified subsidiaries resulting in the change in scope of consolidation): No
- (2) Application of special accounting methods for preparing quarterly consolidated financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
- Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
- Changes in accounting policies due to other reasons: No
- Changes in accounting estimates: No
- Restatement of prior period financial statements: No

(4) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2021	30,563,199	As of March, 2021	-
---------------------	------------	-------------------	---

2) Number of treasury shares at the end of the period

As of June 30, 2021	2,175,400	As of March, 2021	-
---------------------	-----------	-------------------	---

3) Average number of shares during the period (cumulative from the beginning of the fiscal year)

First three months of FY2021	28,377,199	First three months of FY2020	-
------------------------------	------------	------------------------------	---

Note: There are no previous financial results because ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021.

※ This financial results report is not subject to audit procedures by Certified Public Accountants or audit firm.

※ Explanation about proper use of the financial forecast figures, and other special notes

- The forecast figures shown in this report are based on information currently available to the Company and may contain certain uncertainties. Actual business results may materially differ from the forecasted figures due to various factors in the future
- ASKA Pharmaceutical Holdings Co., Ltd. was established through a sole share transfer on April 1, 2021 and there are no previous financial results due to our first consolidated fiscal year.

Quarterly Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

As of June 30,2021

Assets	
Current assets	
Cash and deposits	10,141
Notes, accounts receivable and contract asset	13,571
Merchandise and finished goods	8,927
Work in process	691
Raw materials and supplies	4,434
Other	1,848
Allowance for doubtful accounts	(0)
Total current assets	39,615
Non-current assets	
Property, plant and equipment	12,520
Intangible assets	
Intangible assets in progress	8,421
Other	3,224
Total intangible assets	11,646
Investments and other assets	
Investment securities	12,514
Other	5,439
Allowance for doubtful accounts	(17)
Total investments and other assets	17,935
Total non-current assets	42,102
Total assets	81,717
Liabilities	
Current liabilities	
Notes and accounts payable -trade	3,354
Electronically recorded obligations - operating	2,764
Short(Long)-term loans payable	2,848
Other provision	555
Other	6,443
Total current liabilities	15,966
Non-current liabilities	
Long-term loans payable	12,747
Provision for environmental measures	820
Retirement benefit liabilities	6,533
Other	336
Total non-current liabilities	20,437
Total liabilities	36,403
Net assets	
Shareholders' equity	
Share capital	1,197
Capital surplus	921
Retained earnings	43,814
Treasury shares	(3,288)
Total shareholders' equity	42,645
Accumulated other comprehensive income	
Valuation difference on available-for-sale securities	2,789
Foreign currency translation adjustment	(84)
Remeasurements of defined benefit plans	(36)
Total accumulated other comprehensive income	2,668
Total net assets	45,313
Total liabilities and net assets	81,717

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

(Millions of yen)

First three months of FY2021

Net sales	14,221
Cost of sales	7,531
Gross profit	6,690
Selling, general and administrative expenses	5,501
Operating profit	1,188
Non-operating income	
Interest income	0
Dividend income	130
Equity in earnings of affiliates	64
Other	39
Total non-operating income	234
Non-operating expenses	
Interest expenses	14
Dormant fixed asset costs	53
Other	24
Total non-operating expenses	92
Ordinary profit	1,329
Profit before income taxes	1,329
Income taxes - current	165
Income taxes - deferred	65
Total income taxes	230
Profit	1,098
Profit attributable to owners of parent	1,098

(Consolidated Statements of Income)

(Millions of yen)

First three months of FY2021

Profit	1,098
Other comprehensive income	
Valuation difference on available-for-sale securities	(35)
Remeasurements of defined benefit plans, net of tax	7
Share of other comprehensive income of associates accounted for using equity method	(84)
Total other comprehensive income	(112)
Comprehensive income	986
Details	
Comprehensive income attributable to owners of parent	986

Supplemental Material

(1) Sales of Main Products

S a l e s o f M a i n P r o d u c t s
(F Y 2 0 2 1 Q 1 A c t u a l)

ASKA Pharmaceutical Co., Ltd.

(Millions of yen)

Therapeutic category	Products	FY2020		FY2021		QOQ(%)
		Q1 Actual	FY2020 Actual	Q1 Actual	FY2021 Forecast	
Antihypertensive agent	CANDESARTAN※	3,236	12,329	3,198	10,605	(1.2)
Thyroid hormone	THYRADIN	1,845	7,209	1,945	7,279	5.4
GnRH antagonist	RELUMINA	1,127	5,709	1,788	7,257	58.6
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	1,118	4,334	1,247	5,301	11.5
LH-RH derivative	LEUPRORELIN	1,150	4,502	1,161	3,919	1.0
Dysmenorrhea agent	FREWELL	652	2,952	804	2,655	23.3
Antithyroid agent	MERCAZOLE	361	1,401	381	1,466	5.5
Antihypertensive agent	AMLODIPINE	337	1,294	291	1,102	(13.8)
Amyotrophic lateral sclerosis agent	RILUZOLE	289	1,083	258	1,026	(10.8)
Oral Contraceptives	ANGE	232	908	230	1,016	(0.9)

※Including compounding agents